EUVIMEDSkopri EUVIMED
Systematische ÜbersichtOpen access · CC BY 4.0

Comparative Efficacy and Safety of Different Triple Oral Antidiabetic Therapy Regimens and Insulin‐Based Therapy Regimens Following Dual Therapy Failure in Type 2 Diabetes Mellitus: A Systematic Review and Network Meta‐Analysis

Jie Yu, Chong Rao, Limei Cui, Xinhua Xiao

Diabetes/Metabolism Research and Reviews · 2026-11 · 42 (8)

DOI: 10.1002/dmrr.70252 ↗

At a glance

Systematische Übersicht in Diabetes/Metabolism Research and Reviews, published online on 2026-11-16. Written by Jie Yu and 3 co-authors. 26 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Natural Science Foundation of China.

AstrattDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Aims

The aim of this systematic review and network meta‐analysis was to compare the efficacy and safety of triple oral antidiabetic therapy (3OADs) and insulin‐based therapy in patients with type 2 diabetes after dual therapy failure. Materials and Methods Medline (PubMed), Embase, Web of Science, and Cochrane Library were systematically searched (from inception to September 1, 2023). The network meta‐analysis included randomized clinical trials (RCTs) of 3OADs and/or insulin‐based therapies after dual therapy failure. Mean difference (MD) was extracted for changes in HbA1c and body weight; odds ratio (OR) was extracted for hypoglycemia and adverse events.

Results

Forty‐two articles (13,911 adult patients) were analysed. 3OADs versus insulin‐based therapy showed comparable HbA1c reduction (MD 0.01%; 95% CI, −0.56 to 0.58), weight change (MD ‐1.59 kg; 95% CI, −3.67 to 0.48), hypoglycemia (OR 0.70; 95% CI, 0.37–1.30), and adverse events (OR 1.68; 95% CI, 1.00–2.82) at 22–36 weeks. Sensitivity analysis revealed that 3OADs significantly reduced weight compared with insulin‐based therapy (MD −3.30 kg; 95% CI, −5.56 to −1.05). No significant differences in HbA1c reduction, hypoglycemia incidence, or adverse events were observed between metformin (Met) + dipeptidyl peptidase‐4 inhibitor (DPP‐4i) + sodium‐glucose cotransporter‐2 inhibitor (SGLT‐2i) and other 3OAD regimens. Meanwhile, Met + DPP‐4i + SGLT‐2i had the highest probability of achieving the greatest weight reduction.

Conclusions

Compared with insulin‐based therapy, 3OADs demonstrated comparable glucose‐lowering effects and safety profiles, with a significant weight‐sparing benefit observed in sensitivity analysis. Among all 3OAD combinations, Met + DPP‐4i + SGLT‐2i ranked first for weight loss, without increasing hypoglycemia risk.

Funding

  • National Natural Science Foundation of China

Cite

APA

Yu, J., Rao, C., Cui, L., & Xiao, X. (2026). Comparative Efficacy and Safety of Different Triple Oral Antidiabetic Therapy Regimens and Insulin‐Based Therapy Regimens Following Dual Therapy Failure in Type 2 Diabetes Mellitus: A Systematic Review and Network Meta‐Analysis. Diabetes/Metabolism Research and Reviews, 42(8). https://doi.org/10.1002/dmrr.70252

Vancouver

Yu J, Rao C, Cui L, Xiao X. Comparative Efficacy and Safety of Different Triple Oral Antidiabetic Therapy Regimens and Insulin‐Based Therapy Regimens Following Dual Therapy Failure in Type 2 Diabetes Mellitus: A Systematic Review and Network Meta‐Analysis. Diabetes/Metabolism Research and Reviews. 2026;42(8). doi:10.1002/dmrr.70252

BibTeX
@article{Yu2026,
  author = {Yu, Jie and Rao, Chong and Cui, Limei and Xiao, Xinhua},
  title = {Comparative Efficacy and Safety of Different Triple Oral Antidiabetic Therapy Regimens and Insulin‐Based Therapy Regimens Following Dual Therapy Failure in Type 2 Diabetes Mellitus: A Systematic Review and Network Meta‐Analysis},
  journal = {Diabetes/Metabolism Research and Reviews},
  year = {2026},
  volume = {42},
  number = {8},
  doi = {10.1002/dmrr.70252}
}
Start for free →